NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD

Pharmacogenomics Journal

Volumn 16, Issue 3, 2016, Pages 280-285

  Kakuta, Y ^a   Naito, T ^a   Onodera, M ^a   Kuroha, M ^a   Kimura, T ^a   Shiga, H ^a   Endo, K ^a   Negoro, K ^a   Kinouchi, Y ^b   Shimosegawa, T ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; INORGANIC PYROPHOSPHATASE; MTH2 PROTEIN, HUMAN;

ADULT; AGE; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENDER; GENETIC ASSOCIATION; GENOTYPE; GENOTYPING TECHNIQUE; HAIR LOSS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; JAPANESE (PEOPLE); LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TAQMAN GENOTYPING ASSAY; ULCERATIVE COLITIS; ALOPECIA; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; DOSE RESPONSE; ENZYMOLOGY; ETHNOLOGY; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; JAPAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHENOTYPE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

6-MERCAPTOPURINE; ADULT; ALOPECIA; ANTI-INFLAMMATORY AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; AZATHIOPRINE; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL AGENTS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHENOTYPE; PYROPHOSPHATASES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84931047777     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.43     Document Type: Article

References (24)

1. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-489
2. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 944-947
3. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 1273-1276
4. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-630
5. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395
6. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004; 13: 563-567
7. Chaparro M, Ordas I, Cabre E, Garcia-Sanchez V, Bastida G, Penalva M, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-Term follow-up study of 3931 patients. Inflamm Bowel Dis 2013; 19: 1404-1410
8. Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014; 46: 1131-1134
9. Bourgine J, Garat A, Allorge D, Crunelle-Thibaut A, Lo-Guidice JM, Colombel JF, et al. Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response?. Pharmacogenet Genomics 2011; 21: 313-324
10. Mazor Y, Koifman E, Elkin H, Chowers Y, Krivoy N, Karban A, et al. Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease. Curr Drug Saf 2013; 8: 181-185
11. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-1030
12. Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagahama T, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2009; 24: 1258-1264
13. Ban H, Andoh A, Tanaka A, Tsujikawa T, Sasaki M, Saito Y, et al. Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease. Intern Med 2008; 47: 1645-1648
14. Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014; 46: 1017-1020
15. Yang SK, Ye BD, Song K. ATG16L1 contributes to Crohn's disease susceptibility in Koreans: overmuch concern for ethnic difference?. Gut 2014; 64: 687-688
16. Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y, Hata A. Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients. J Hum Genet 2007; 52: 575-583
17. Hirano A, Yamazaki K, Umeno J, Ashikawa K, Aoki M, Matsumoto T, et al. Association study of 71 European Crohn's disease susceptibility loci in a Japanese population. Inflamm Bowel Dis 2013; 19: 526-533
18. NCI N, DHHS. National Cancer Institute, Common Terminology Criteria for Adverse Events v4. NIH publication # 09-7473 2009
19. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003; 38: 740-746
20. Takagi Y, Setoyama D, Ito R, Kamiya H, Yamagata Y, Sekiguchi M. Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: comparison with MTH1 and MTH2. J Biol Chem 2012; 287: 21541-21549
21. Tanaka Y, Manabe A, Nakadate H, Kondoh K, Nakamura K, Koh K, et al. Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients. Leuk Lymphoma 2014; 55: 1126-1131
22. Stocco G, Yang W, Crews KR, Thierfelder WE, Decorti G, Londero M, et al. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 2012; 21: 4793-4804
23. Roberts RL, Wallace MC, Seinen ML, Krishnaprasad K, Chew A, Lawrance I, et al. PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. Am J Gastroenterol 2014; 109: 925-927
24. Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46: 355-367